The FDA comes up with a plan for naming biosimilars; Exelixis wins a Swiss regulatory OK for cobimetinib;

@FierceBiotech: UCSF cardiology chief builds a case for two new targets for heart drugs. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I'm happy to see $MDVN back in a late-stage development race. It's been awhile, and they're smart, aggressive players. More from FiercePharmaMarketing | Follow @JohnCFierce

> The FDA hopes that adding a simple suffix to a biosimilar name will avoid any confusion about whether the original drug or the knockoff is being prescribed. Story

> South San Francisco-based Exelixis says that Swiss officials have approved cobimetinib for advanced melanoma--a regulatory first. Release

Medical Device News

@FierceMedDev: Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Providence Medical receives $12M in financing to expand sales of its spinal fusion devices. Story | Follow @VarunSaxena2

@EmilyWFierce: Recipharm strikes development deal for RedHill's bacteria-fighter candidate. FierceCRO item | Follow @EmilyWFierce

> Greatbatch grabs Lake Regional Medical for $730M to expand surgical offerings. News

> Abbott denies FT report that it's preparing $25B bid for St. Jude Medical. Article

Pharma News

@FiercePharma: Academic docs and biotechs partner with veterinarians to find cancer cures. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing article | Follow @CarlyHFierce

> Impatient Horizon accuses Depomed of stalling its shareholder meeting plans. Report

> AbbVie scores one against FTC in pay-for-delay AndroGel suit. News

> Lilly, Boehringer amp up fight against Lantus with U.K. biosim launch. Article

Vaccines News

> Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials. News

> Valneva licenses EB66 technology to develop human, veterinary vaccines. Report

> Takeda expands vaccine platform rights with Nanotherapeutics agreement. More

> FluGen reels in $12M to fund PhI of its universal flu jab. Story

> Scripps Research Institute, J&J test 'universal' flu vaccine in mice, monkeys. Article

CRO News

> WuXi inks lab testing pact with Chinese Lee's Pharm. News

> Germany lists 54 GVK suspensions as EU comes down on Indian CRO. More

> Recipharm strikes development deal for RedHill's bacteria-fighter candidate. Report

> CRO field to grow nearly 10% annually through 2019, report says. Story

> India's Accutest Research Labs expands into Latin America. Article

Pharma Manufacturing News

> Shire works deal with Sanquin so it can boost production of rare disease drug. More

> Woodcock says FDA will keep new plant quality grades a secret. Report

> Sterilization specialist on expansion streak. Item

> Sucampo gets control of Amitiza production in deal for Japanese company. Story

> Novo picks Clayton, NC, for its first U.S. API plant. Article

Pharma Asia News

> India's Gujarat state moves closer to country's first medical device testing lab. Story

> China's Shenzhen Hepalink keeps N. American deal stream rolling with Cytovance. More

> Oncology trials in China may see pilot program for 60-day IND decision. Story

> BD Life Science buys Silicon Valley-based Cellular Research, part of Decheng portfolio. Article

> Japan's PAFSC to review application from Takeda on glatiramer this week. Item

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.